期刊文献+

丙型肝炎病毒CTL表位基因真核表达载体的构建及稳定转染细胞系的建立

Construction of eukaryotic expression vector of HCV CTL epitopes and establishment of stable transfected CHO cell line
下载PDF
导出
摘要 目的构建含丙型肝炎病毒(HCV)复合多表位基因的真核表达载体,转染CHO细胞,建立稳定转染细胞系。方法通过生物信息学预测分析的方法得到涵盖HCV不同基因型与小鼠H2复合体的多个细胞毒性T淋巴细胞(CTL)表位,串联后人工合成基因序列,将其克隆入真核表达载体pEGFP-N3中,然后利用脂质体法转染CHO细胞,通过持续G418筛选建立稳定转染细胞株。最后通过荧光显微镜观察、RT-PCR和Western Blot等方法证实多表位基因的表达。结果所构建的含有HCV复合多表位基因的真核表达载体pEGFP-mEpi在CHO细胞中能稳定表达。结论真核表达载体的成功构建和稳定转染CHO细胞系的建立为进一步研究复合多表位疫苗的基因免疫奠定了基础。 Objective To construct eukaryotic expression vector of hepatitis C virus(HCV) cytotoxic T-lymphocyte(CTL) epitopes,and to establish stable transfected CHO cell-lines.Methods The HCV CTL epitopes of different genotypes and the mouse H2 complex were predicted by bioinformatics,then synthesized and inserted into eukaryotic expression vector pEGFP-N3.The recombinant vector was transfected into CHO cells by lipofectamine 2000.After screening with G418,stably transfected CHO cell line was established.The expression of HCV multi-epitopes was identified by RT-PCR and western-blot and immunofluorescence.Results The eukaryotic expression vector was constructed successfully.The stable transfected CHO cell line was established.Conclusion The establishment of stable transfected CHO cell line and the expression of the target gene provide solid foundation for further experimental studies.
出处 《临床肝胆病杂志》 CAS 2011年第1期45-48,共4页 Journal of Clinical Hepatology
基金 国家“863”专项课题(2007AA02Z441) 国家“十一五”重大科技专项(2009ZX10004-7l5)
关键词 肝炎病毒属 转染 基因表达 表位 T淋巴细胞 T淋巴细胞 细胞毒性 hepacivirus transfection gene expression epitopes, T-lymphocyte T-lymphocytes, cytotoxic
  • 相关文献

参考文献14

  • 1StolI-Keller F, Barth H, Fafi-Kremer S, et al. Development of hepatitis C virus vaccines: challenges and progress[J]. Expert Rev Vaccines,2009, 8(3): 333-345.
  • 2Yerly D, Heckerman D, Allen TM, et al. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance[J]. J Virol,2008, 82(6): 3147-3153.
  • 3Takao Y, Yamada A, Yutani S, et al.ldentification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) lb with the potentiality to generate cytotoxic T lymphocytes in HCVlb(+) HLA-A24(+) patients[J]. Hepatol Res, 2007, 37(3): 186-195.
  • 4Vider-Shalit T, Raffaeli S, Louzoun Y. Virus-epitope vaccine design: informatic matching the HLA-1 polymorphism to the virus genome[J]. Mol Immunol, 2007, 44(6): 1253-1261.
  • 5Shi L, Liu S, Fan GX, et ai. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes[J]. Viral Immunol, 2006, 19(4): 702-711.
  • 6Chang KM, Gruener NH.Southwood S, et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C[J]. J Immunol, 1999, 162(2): 1156- 1164.
  • 7Sallberg M, Zhang ZX, Chen M. et al. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein[J]. J Gen Virol, 1996, 77(Ptl 1): 2721-2728.
  • 8Sarobe P, Lasarte J J, Garc i a N, et al. Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins[J]. J Viral Hepat, 2006, 13(1): 47-55.
  • 9李端,谢玉为,薛小平,白雪帆,贾战生.中国丙型肝炎病毒细胞毒性T淋巴细胞表位预测及其多表位疫苗设计[J].中华肝脏病杂志,2009,17(10):786-787. 被引量:3
  • 10Hurwitz JL, Zhan X, Brown SA, et al. HIV-1 vaccine development:tackling virus diversity with a multi- envelope cocktail[J]. Front Biosci, 2008, 13: 609-620.

二级参考文献8

  • 1薛付忠,王洁贞,胡平,郭亦寿,李国荣.中国多表位疫苗设计的HLA-Ⅰ积累表型频率空间预测系统(英文)[J].免疫学杂志,2005,21(2):136-141. 被引量:4
  • 2Webster DE Klenerman P, Collier J, et al. Development of novel treatments for hepatitis C. Lancet Infect Dis, 2009, 9: 108-117.
  • 3Soler E, Houdebine LM. Preparation of recombinant vaccines. Biotechnol Annu Rev, 2007, 13: 65-94.
  • 4Hurwitz JL, Zhan X, Brown SA, et al. HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail. Front Biosci, 2008, 13: 609-620.
  • 5Stoll-Keller F, Barth H, Fafi-Kremer S, et al. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines, 2009, 8: 333-345.
  • 6Encke J, Radunz W, Eisenbach C, et al. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection. Eur J Clin Invest, 2007, 37: 396-406.
  • 7Azizi A, Diaz-Mitoma F. Viral peptide immunogens: current chal- lenges and opportunities. J Pept Sci, 2007, 13: 776-786.
  • 8Shi L, Liu S, Fan GX, et al. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes. Viral Immunol, 2006, 19: 702-711.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部